FDA approves AbbVie's drug to treat chronic hepatitis C

The Food and Drug Administration approved AbbVie's Viekira extended release tablets for the treatment of patients with chronic genotype 1 hepatitis C virus.

Viekira XR is a co-formulation of four active ingredients — dasabuvir, ombitasvir, paritaprevir and ritonavir — that are present in Abbvie's Viekira Pak, which is already on the market.

Viekira XR, taken once daily as three oral tablets, represents the first treatment available for adults with chronic genotype 1 hepatitis C virus that combines three direct-acting antivirals.

North Chicago, Ill.-based AbbVie did not specify when Viekira XR will hit the market.

More articles about the drug market:

'Pain refugees' travel out of Montana for access to opioid prescriptions
Sen. Bernie Sanders' DNC speech tackles high prescription drug costs: 4 things to know
Eli Lily exceeds 2Q expectations thanks to new drug sales

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars